Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 30Neoplasms, Plasma Cell 7Breast Neoplasms 5Prostatic Neoplasms 3Pain 3Spinal Cord Compression 2Hematologic Neoplasms 2Bone Neoplasms 2Bone Diseases 2Renal Insufficiency 1Paraproteinemias 1Osteonecrosis 1Osteolysis 1Neoplastic Processes 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Hematologic Diseases 1Fractures, Bone 1Disease Progression 1Bone Marrow Diseases 1Blood Protein Disorders 1

Interventions

Dexamethasone 6Lenalidomide 4Bortezomib 4pomalidomide 3isatuximab 2daratumumab 2ricolinostat 1nirogacestat 1ficlatuzumab 1Zoledronic Acid 1Vorinostat 1Ranitidine 1KW-2478 1Hsp90 inhibitor KU757 1Erlotinib Hydrochloride 1Diphenhydramine 1Denosumab 1Cyclophosphamide 1CLR1404 1Acetaminophen 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blood Protein Disorders × Zoledronic Acid × Plasma cell × Clear all
NCT01345019 2022-11-08

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Amgen

Phase 3 Completed
1,718 enrolled 22 charts
Other hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Bone Diseases, Bone Marrow Diseases, Bone Neoplasms, Hematologic Diseases, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Paraproteinemias, Spinal Cord Compression, Hematologic Neoplasms, Fractures, Bone, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡